Thioridazine protects the mouse from a virulent infection by Salmonella enterica serovar Typhimurium 74

International Journal of Antimicrobial Agents

Volumn 35, Issue 2, 2010, Pages 174-176

  Dasgupta, Asish ^a   Mukherjee, Sayanti ^a   Chaki, Shaswati ^a   Dastidar, Sujata G ^a   Hendricks, Oliver ^b,c   Christensen, Jørn B ^d   Kristiansen, Jette E ^d,e   Amaral, Leonard ^f  

^a Department of Microbiology   (India)

^b Sønderjylland Hospital   (Denmark)

^c King Christian the Xth Hospital   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e INRG ^*  (Denmark)

^f INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

Author keywords

55 kDa virulence protein; PmrA B; Protection; Salmonella Typhimurium 74; Thioridazine; Two step regulon; Virulent infection

Indexed keywords

LIPID A; LIPOPOLYSACCHARIDE; PHENOTHIAZINE; THIORIDAZINE; VIRULENCE FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL SALMONELLOSIS; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL OUTER MEMBRANE; BACTERIAL VIRULENCE; CELLULAR DISTRIBUTION; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG MECHANISM; INFECTION PREVENTION; LIPOGENESIS; MALE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PHAGOLYSOSOME; PRIORITY JOURNAL; PROTEIN HYDROLYSIS; REGULON; SALMONELLA ENTERICA; SALMONELLA TYPHIMURIUM; SEROTYPE;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTERIAL PROTEINS; BLOOD; COLONY COUNT, MICROBIAL; LIVER; MALE; MICE; MICROBIAL VIABILITY; NEUTROPHILS; SALMONELLA INFECTIONS, ANIMAL; SALMONELLA TYPHIMURIUM; SPLEEN; SURVIVAL ANALYSIS; THIORIDAZINE; VIRULENCE FACTORS;

EID: 72649096227     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.09.027     Document Type: Article

References (11)

1. Kristiansen J.E. Dyes, antipsychotic drugs, and antimicrobial activity. Fragments of a development, with special reference to the influence of Paul Ehrlich. Dan Med Bull 36 (1989) 178-185
2. Martins M., Dastidar S.G., Fanning S., Kristiansen J.E., Molnar J., Pagès J.M., et al. Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant Gram-negative infections: mechanisms for their direct and indirect activities. Int J Antimicrob Agents 31 (2008) 198-208
3. Dasgupta A, Dastidar SG, Shirataki Y, Motohashi N. Antibacterial activity of artificial phenothiazines and isoflavones from plants. In: Motohashi N, volume editor, Gupta RR, series editor. Bioactive heterocycles VI; flavonoids and anthocyanins in plants, and latest bioactive heterocycles I. Berlin, Germany: Springer-Verlag; 2008. p. 67-132.
4. Amaral L., Kristiansen J.E., Frolund Thomsen V., and Markovich B. The effects of chlorpromazine on the outer cell wall of Salmonella typhimurium in ensuring resistance to the drug. Int J Antimicrob Agents 14 (2000) 225-229
5. Gunn J.S. The Salmonella PmrAB regulon: lipopolysaccharide modifications, antimicrobial peptide resistance and more. Trends Microbiol 16 (2008) 284-290
6. Ordway D., Viveiros M., Leandro C., Bettencourt R., Almeida J., Martins M., et al. Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 47 (2003) 917-922
7. Ordway D., Viveiros M., Leandro C., Arroz M.J., and Amaral L. Intracellular activity of clinical concentrations of phenothiazines including thioridazine against phagocytosed Staphylococcus aureus. Int J Antimicrob Agents 20 (2002) 34-43
8. + transport enhance intracellular killing of M. tuberculosis by non-killing macrophages. In Vivo 21 (2008) 69-75
9. Martins M., Viveiros M., Kristiansen J.E., Molnar J., and Amaral L. The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis. In Vivo 21 (2007) 771-775
10. Martins A., Spengler G., Rodrigues L., Viveiros M., Ramos J., Martins M., et al. pH modulation of efflux pump activity of multi-drug resistant Escherichia coli: protection during its passage and eventual colonization of the colon. PLoS One 4 (2009) e6656
11. Dutta N.K., Annadurai S., Mazumdar K., Dastidar S.G., Kristiansen J.E., Molnar J., et al. Potential management of resistant microbial infections with a novel non-antibiotic: the anti-inflammatory drug diclofenac sodium. Int J Antimicrob Agents 30 (2007) 242-249